| Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ |
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System™ (“AYON”). |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation (APYX) Q1 2025 Earnings Call Transcript |
Apyx Medical Corporation (NASDAQ:APYX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Jeremy Feffer – LifeSci Advisors Charlie Goodwin – Chief Executive Officer Matt Hill – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Capital Group Sam Eiber – BTIG Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-11 10:34:33 |
Czytaj oryginał (ang.) |
| Renuvion Introduces Television Star Dolores Catania as Chief of Confidence |
Beloved Personality of "The Real Housewives of New Jersey" Provides a Real Take on the Problem of Loose Skin and the Power of Body Contouring Technology CLEARWATER, Fla. , May 1, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® today announces Dolores Catania as the Chief of Confidence for the brand's Renew You consumer marketing campaign which exemplifies the brand's ability to reshape bodies and lives. |
prnewswire.com |
2025-05-01 13:00:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures |
Two studies report favorable clinical outcomes and safety data for Renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominoplasty1. |
globenewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 |
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. |
globenewswire.com |
2025-04-24 12:45:00 |
Czytaj oryginał (ang.) |
| Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener" |
Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla. , March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. |
prnewswire.com |
2025-03-25 11:00:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation (APYX) Q4 2024 Earnings Call Transcript |
Apyx Medical Corporation (NASDAQ:APYX ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Operator Greetings. Welcome to the Apyx Medical Fourth Quarter and Full Year 2024 Conference Call. |
seekingalpha.com |
2025-03-13 13:48:22 |
Czytaj oryginał (ang.) |
| Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates |
Apyx Medical (APYX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2025-03-13 11:15:33 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™ |
Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite |
globenewswire.com |
2025-01-06 10:00:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference |
CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: |
globenewswire.com |
2024-11-12 18:05:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript |
Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Ben Haynor - Lake Street Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-08 15:39:44 |
Czytaj oryginał (ang.) |
| Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates |
Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago. |
zacks.com |
2024-11-08 11:15:29 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering |
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024. |
globenewswire.com |
2024-11-08 09:05:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook |
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025. |
globenewswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024 |
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. |
globenewswire.com |
2024-10-25 12:00:00 |
Czytaj oryginał (ang.) |
| Apyx (APYX) Upgraded to Buy: Here's What You Should Know |
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-10-03 17:01:18 |
Czytaj oryginał (ang.) |
| Renuvion Named #1 Trusted Body Contouring Technology by Doctors* |
Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla. |
prnewswire.com |
2024-08-13 12:10:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript |
Apyx Medical Corporation (NASDAQ:APYX ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this time all participants have been placed in a listen-only more. |
seekingalpha.com |
2024-08-11 10:39:07 |
Czytaj oryginał (ang.) |
| Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates |
Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago. |
zacks.com |
2024-08-08 23:30:25 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health |
Renuvion is the only device FDA-cleared for contracting subcutaneous tissue CLEARWATER, Fla. , June 26, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical technology. |
prnewswire.com |
2024-06-26 11:30:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation (APYX) Q1 2024 Earnings Call Transcript |
Apyx Medical Corporation (NASDAQ:APYX ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matt Hill - Chief Financial Officer Conference Call Participants Phillip Paul Dantoin - Piper Sandler Frank Takkinen - Lake Street Capitals Matt Hewitt - Craig-Hallum Capital George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the First Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. [Operator Instructions]. |
seekingalpha.com |
2024-05-11 22:33:08 |
Czytaj oryginał (ang.) |
| Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates |
Apyx Medical (APYX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.10 per share a year ago. |
zacks.com |
2024-05-09 13:21:07 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 |
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th. Management will host a conference call at 8:00 a.m. Eastern Time on May 9th to discuss the results of the quarter, and to host a question and answer sessi. |
businesswire.com |
2024-04-25 11:30:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users' Summit |
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Apyx Medical”; “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users' Summit is taking place in Las Vegas from April 12-13, 2024. The Renuvion Users' Summit brings together a diverse group of dedicated professionals in cosmetic and plastic surgery from 13 countries to share new research, applications, and c. |
businesswire.com |
2024-04-11 11:30:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript |
Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-21 12:12:10 |
Czytaj oryginał (ang.) |
| Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates |
Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.17 per share a year ago. |
zacks.com |
2024-03-21 11:15:20 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook |
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary: Total revenue of $14.7 million, an increase of 16% year-over-year. |
businesswire.com |
2024-03-21 09:00:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024 |
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st. Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a questio. |
businesswire.com |
2024-03-04 09:30:00 |
Czytaj oryginał (ang.) |
| Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting |
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that its Renuvion technology will be featured in three educational sessions at the upcoming American Academy of Cosmetic Surgery's 40th Annual Scientific Meeting, to be held in New Orleans, LA from February 22 – 24. “Apyx Medical is pleased to see Renuvion featured. |
businesswire.com |
2024-02-21 09:30:00 |
Czytaj oryginał (ang.) |